Products

Biotinylated Human HLA-A*11:01&B2M&EGFR WT Monomer, E. coli

Overview Specification

Product Name	Biotinylated Human HLA-A*11:01&B2M&EGFR WT Monomer, E. coli
Cat. No.	MHCRP-0401
Category	Proteins & Peptides
Product Description	Recombinant Biotinylated Human HLA-A11:01&B2M&EGFR WT (KITDFGLAK) Monomer Protein is expressed from E. coli* with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and KITDFGLAK peptide.
Size	100/500 μg
Format	Liquid. Supplied as 0.22 μm filtered solution in 20 mM Tris, 200 mM NaCl (pH 8.0).
Storage	Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping Temp	Shipped at ambient temperature.
Lead Time	Product delivery time depends on the supplier.
Species	Human
Expression Host	E. coli
Accession No	AAV53343.1(HLA-A*11:01)&P61769(B2M)&KITDFGLAK
Tag	C-His-Avi
Tag Position	C-terminus
Molecular Type	Monomer
Molecular Weight (MV)	The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
Gene Synonyms	TERT; ILAKFLHWL
Purity	> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC.
Amino Acid Range	Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M), and KITDFGLAK peptide
Activity	Immobilized biotinylated human HLA-A11:01&B2M&EGFR WT (KITDFGLAK) monomer, His-Avi tag at 2 μg/mL (100 μL/well) on the streptavidin precoated plate (5 μg/mL). Dose response curve for HLA-A11:01&B2M&EGFR TCR, hFc tag with the EC50 of 32.6 ng/mL determined by ELISA.
Product Background	The human telomerase catalytic subunit human telomerase reverse transcriptase (hTERT) is expressed in many human cancer cells derived from multiple tissues, but infrequently in normal cells. Thus, hTERT is an attractive candidate target for tumor immunotherapy. hTERT:540–548 peptide (p540, ILAKFLHWL) has been identified as an effective HLA-A*0201-restricted T-cell epitope, an effective T-cell-based cancer treatment, including vaccines, against hTERT will likely require the identification of other MHC class I-restricted epitopes in this antigen.
Biotinylated	Yes

For research or industrial raw materials, not for personal medical use!